Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$78.2 million.

  • Nurix Therapeutics' Net Income towards Common Stockholders fell 3359.92% to -$78.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$264.5 million, marking a year-over-year decrease of 3662.16%. This contributed to the annual value of -$264.5 million for FY2025, which is 3662.16% down from last year.
  • As of Q4 2025, Nurix Therapeutics' Net Income towards Common Stockholders stood at -$78.2 million, which was down 3359.92% from -$86.4 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' Net Income towards Common Stockholders peaked at -$24.3 million during Q1 2021, and registered a low of -$86.4 million during Q3 2025.
  • For the 5-year period, Nurix Therapeutics' Net Income towards Common Stockholders averaged around -$45.0 million, with its median value being -$43.0 million (2022).
  • As far as peak fluctuations go, Nurix Therapeutics' Net Income towards Common Stockholders crashed by 44804.75% in 2021, and later surged by 4652.76% in 2023.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Net Income towards Common Stockholders stood at -$37.7 million in 2021, then decreased by 23.95% to -$46.7 million in 2022, then rose by 10.19% to -$42.0 million in 2023, then tumbled by 39.55% to -$58.5 million in 2024, then plummeted by 33.6% to -$78.2 million in 2025.
  • Its last three reported values are -$78.2 million in Q4 2025, -$86.4 million for Q3 2025, and -$43.5 million during Q2 2025.